Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - pemetrexed - powder for solution for infusion - pemetrexed 100 mg/vial - pemetrexed - pemetrexed - alimta in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - olanzapine - tablets - olanzapine 5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - olanzapine - tablets - olanzapine 7.5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - olanzapine - tablets - olanzapine 7.5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - olanzapine - tablets - olanzapine 10 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder :in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - olanzapine - tablets - olanzapine 10.0 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Izraēla - angļu - Ministry of Health

eli lilly israel ltd, israel - olanzapine - tablets orodispersible - olanzapine 5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zyprexa is indicated for the management of the manifestations of psychotic disorders. zyprexa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zyprexa is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zyprexa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.